BTK inhibitor monotherapy is foundational across several B-cell malignancies, with newer, more selective agents designed to preserve efficacy while improving tolerability relative to first-in-class ...

Key opportunities in the B-cell inhibitors market for non-oncology diseases include the rising demand for targeted immunomodulatory therapies, driven by increasing autoimmune disorder prevalence.

“The full end-to-end clinical pathway - from blood draw at a collection site through to result delivery to the ordering clinician - has now been successfully completed in a routine clinical setting,” ...

Dr. Nicoletta Colombo breaks down KEYNOTE B96 showing Keytruda plus paclitaxel, with or without Avastin, improves survival in platinum-resistant ovarian cancer. The phase 3 KEYNOTE B96 trial showed ...

Co-occurring alterations in EGFR-mutant NSCLC are increasingly detected via broad NGS and may signal aggressive biology, prompting interest in escalation strategies that address concurrent drivers.